Bevacizumab-Bvzr
Brand Names: Zirabev
Methodology & AI Transparency ⓘ
Bevacizumab-Bvzr Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Supplied in 400 mg/16mL Injection, Solution and 100 mg/4mL Injection, Solution and manufactured/labeled by Pfizer Laboratories Div Pfizer Inc (NDC 0069-0342, 0069-0315), Bevacizumab-Bvzr operates within intravenous-route vascular endothelial growth factor inhibitor treatment algorithms requiring prescription authorization.
- 2 Real-world patient consensus: 83% patient "Worth It" rating across 14 anonymous logs for Bevacizumab-Bvzr (RxNorm RXN-00690342-2280).
- 3 Typical cash cost range: Public pharmacy ledger: $66.01 low cash benchmark vs. $161.72 chain retail average ($1.4200/unit CMS NADAC).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Bevacizumab-Bvzr: nausea (9.3%), headache (7.5%), dizziness (5.3%).
Ask our AI Specialists anything about Bevacizumab-Bvzr
Bevacizumab-Bvzr Mechanism, CYP450 Pathways & DailyMed Monograph
Supplied in 400 mg/16mL Injection, Solution and 100 mg/4mL Injection, Solution and manufactured/labeled by Pfizer Laboratories Div Pfizer Inc (NDC 0069-0342, 0069-0315), Bevacizumab-Bvzr operates within intravenous-route vascular endothelial growth factor inhibitor treatment algorithms requiring prescription authorization.
Delivered via 400 mg/16mL Injection, Solution and 100 mg/4mL Injection, Solution (intravenous-route; NDC 0069-0342, 0069-0315), Bevacizumab-Bvzr mediates vascular endothelial growth factor inhibitor physiological effects manufactured/labeled by Pfizer Laboratories Div Pfizer Inc with dose-dependent receptor occupancy and systemic clearance.
With Approximately 6–16 hours terminal plasma half-life for Bevacizumab-Bvzr residence kinetics and Complete (~100%) parenteral systemic delivery for Bevacizumab-Bvzr (400 mg/16mL Injection, Solution) bioavailability, Bevacizumab-Bvzr undergoes phase i/ii hepatic conjugation of bevacizumab-bvzr coupled with glomerular and tubular renal excretion and establishes therapeutic activity over rapid intravascular/parenteral onset within 15–45 minutes after bevacizumab-bvzr administration.
Standard adult regimens span 400 mg/16mL Injection, Solution, 100 mg/4mL Injection, Solution. Prescribers screen specifically against prior anaphylaxis, angioedema, or severe hypersensitivity to bevacizumab-bvzr or bevacizumab-bvzr excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 bevacizumab-bvzr spl, while community micro-logs most frequently note nausea (9.3% of reports), headache (7.5% of reports), dizziness (5.3% of reports).
Avoid overlapping vascular endothelial growth factor inhibitor prescriptions alongside Bevacizumab-Bvzr to prevent cumulative receptor toxicity.
Botanical enzyme modulators may alter oral first-pass exposure of Bevacizumab-Bvzr; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Bevacizumab-Bvzr or Bevacizumab-Bvzr excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 Bevacizumab-Bvzr SPL
Logged Side-Effect Incidence (14 Reports)
Bevacizumab-Bvzr Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Bevacizumab-Bvzr)
Human clinical trial evidence for Bevacizumab-Bvzr is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Bevacizumab-Bvzr Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.4200/unit (~$42.60/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $161.72 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 14 Anonymous DotMD Community Micro-Logs | $66.01 / mo | View logs ↓ |
| Sesame Direct Cash-Pay Prescriber Network (Licensed Telehealth Cash Program) | State-licensed clinician review • ~1d mail fulfillment | $29.00 consult | Program details |
Bevacizumab-Bvzr Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Bevacizumab-Bvzr RxNorm Concept ID | RXN-00690342-2280 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.4200 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $161.72 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $66.01 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 83.00% Worth It (14 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Bevacizumab-Bvzr Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Bevacizumab-Bvzr integrating DailyMed SPL (2026-07-01), CMS NADAC ($1.4200/unit), and 14 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Bevacizumab-Bvzr community threads and patient logs by age, biological sex, dosage, and treatment duration.